Symbols / UNCY Stock $7.37 -4.47% Unicycive Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
UNCY (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.

Stock Fundamentals
Scroll to Statements
Market Cap 185.88M Enterprise Value 153.43M Income -26.55M Sales — Book/sh 1.36 Cash/sh 1.64
Dividend Yield — Payout 0.00% Employees 21 IPO — P/E — Forward P/E 0.86
PEG — P/S — P/B 5.40 P/C — EV/EBITDA -5.20 EV/Sales —
Quick Ratio 2.18 Current Ratio 2.58 Debt/Eq 0.39 LT Debt/Eq — EPS (ttm) -1.67 EPS next Y 8.58
EPS Growth — Revenue Growth — Earnings 2026-03-30 ROA -45.66% ROE -141.15% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 25.24M Shs Float 22.82M Short Float 7.43%
Short Ratio 4.00 Short Interest — 52W High 11.00 52W Low 3.71 Beta 1.80 Avg Volume 557.36K
Volume 365.91K Target Price $39.89 Recom None Prev Close $7.71 Price $7.37 Change -4.47%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$39.89
Mean price target
2. Current target
$7.37
Latest analyst target
3. DCF / Fair value
$-16.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.37
Low
$15.00
High
$90.00
Mean
$39.89

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Benchmark Speculative Buy → Speculative Buy $15
2026-04-02 main Guggenheim Buy → Buy $40
2025-10-29 main HC Wainwright & Co. Buy → Buy $22
2025-09-15 main Benchmark Speculative Buy → Speculative Buy $21
2025-04-21 init Guggenheim — → Buy $6
2025-04-11 reit HC Wainwright & Co. Buy → Buy $8
2025-04-01 main HC Wainwright & Co. Buy → Buy $8
2025-01-29 reit HC Wainwright & Co. Buy → Buy $4
2025-01-08 main HC Wainwright & Co. Buy → Buy $4
2024-11-22 reit Benchmark Speculative Buy → Speculative Buy $3
2024-11-14 main HC Wainwright & Co. Buy → Buy $4
2024-11-12 reit HC Wainwright & Co. Buy → Buy $3
2024-10-09 reit HC Wainwright & Co. Buy → Buy $3
2024-09-06 reit Benchmark Speculative Buy → Speculative Buy $3
2024-09-03 reit HC Wainwright & Co. Buy → Buy $3
2024-08-15 main HC Wainwright & Co. Buy → Buy $3
2024-07-10 reit HC Wainwright & Co. Buy → Buy $5
2024-06-25 reit HC Wainwright & Co. Buy → Buy $5
2024-06-03 reit Benchmark Speculative Buy → Speculative Buy $3
2024-05-31 reit Benchmark Speculative Buy → Speculative Buy $3
News
RSS: Latest UNCY news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-25 AGGARWAL GAURAV Director — 652,900 — —
2025-02-18 AGGARWAL GAURAV Director — 1,400,000 — —
2024-10-09 AGGARWAL GAURAV Director — 5,500,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
0.68
-29.02%
0.95
Operating Revenue
0.00
0.00
-100.00%
0.68
-29.02%
0.95
Operating Expense
29.52
-8.10%
32.12
+49.74%
21.45
+12.87%
19.00
Research And Development
9.12
-54.43%
20.01
+55.12%
12.90
+3.75%
12.44
Selling General And Administration
20.40
+68.52%
12.10
+41.61%
8.55
+30.15%
6.57
General And Administrative Expense
20.40
+68.52%
12.10
+41.61%
8.55
+30.15%
6.57
Other Gand A
20.40
+68.52%
12.10
+41.61%
8.55
+30.15%
6.57
Total Expenses
29.52
-8.10%
32.12
+49.74%
21.45
+12.87%
19.00
Operating Income
-29.52
+8.10%
-32.12
-54.60%
-20.77
-15.08%
-18.05
Total Operating Income As Reported
-29.52
+8.10%
-32.12
-54.60%
-20.77
-15.08%
-18.05
EBITDA
-25.91
+28.48%
-36.23
-20.05%
-30.18
-68.68%
-17.89
Normalized EBITDA
-27.93
+8.20%
-30.43
-53.10%
-19.88
-11.09%
-17.89
Reconciled Depreciation
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
EBIT
-26.48
+27.75%
-36.66
-20.34%
-30.46
-68.75%
-18.05
Total Unusual Items
2.02
+134.83%
-5.80
+43.69%
-10.30
0.00
Total Unusual Items Excluding Goodwill
2.02
+134.83%
-5.80
+43.69%
-10.30
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Pretax Income
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Non Operating Interest Income Expense
0.94
-20.92%
1.19
+123.26%
0.53
+8983.33%
-0.01
Interest Expense Non Operating
0.07
+0.00%
0.07
-13.41%
0.08
+1266.67%
0.01
Net Interest Income
0.94
-20.92%
1.19
+123.26%
0.53
+8983.33%
-0.01
Interest Expense
0.07
+0.00%
0.07
-13.41%
0.08
+1266.67%
0.01
Interest Income Non Operating
1.01
-19.75%
1.26
+105.04%
0.61
0.00
Interest Income
1.01
-19.75%
1.26
+105.04%
0.61
0.00
Other Income Expense
2.02
+134.83%
-5.80
+43.69%
-10.30
—
Gain On Sale Of Security
2.02
+134.83%
-5.80
+43.69%
-10.30
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Income From Continuing Operation Net Minority Interest
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Income From Continuing And Discontinued Operation
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Net Income Continuous Operations
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Normalized Income
-28.58
+7.60%
-30.93
-52.79%
-20.24
-12.09%
-18.06
Net Income Common Stockholders
-26.55
+29.79%
-37.82
-20.42%
-31.41
-73.95%
-18.06
Diluted EPS
—
-5.65
+55.86%
-12.80
-6.67%
-12.00
Basic EPS
—
-5.65
+55.86%
-12.80
-6.67%
-12.00
Basic Average Shares
—
6.70
+172.97%
2.45
+62.98%
1.51
Diluted Average Shares
—
6.70
+172.97%
2.45
+62.98%
1.51
Diluted NI Availto Com Stockholders
-26.55
+29.79%
-37.82
-20.42%
-31.41
-73.95%
-18.06
Preferred Stock Dividends
—
1.09
+26.30%
0.87
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
49.13
+55.16%
31.67
+123.16%
14.19
+403.58%
2.82
Current Assets
48.96
+58.20%
30.95
+130.97%
13.40
+406.77%
2.64
Cash Cash Equivalents And Short Term Investments
41.27
+57.86%
26.14
+169.48%
9.70
+2032.09%
0.46
Cash And Cash Equivalents
29.20
+11.69%
26.14
+169.48%
9.70
+2032.09%
0.46
Cash Financial
29.20
+11.69%
26.14
+169.48%
9.70
+2032.09%
0.46
Other Short Term Investments
12.07
0.00
—
—
Prepaid Assets
6.52
+68.63%
3.87
+14.65%
3.37
+66.16%
2.03
Current Deferred Assets
—
—
—
—
Other Current Assets
1.17
+24.71%
0.94
+188.92%
0.33
+104.40%
0.16
Total Non Current Assets
0.17
-75.83%
0.72
-9.09%
0.79
+355.17%
0.17
Net PPE
0.17
-75.83%
0.72
-9.09%
0.79
+355.17%
0.17
Gross PPE
0.25
-67.59%
0.76
-6.06%
0.81
+346.41%
0.18
Accumulated Depreciation
-0.07
-84.62%
-0.04
-143.75%
-0.02
-128.57%
-0.01
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.11
-83.26%
0.65
-15.80%
0.77
+403.95%
0.15
Machinery Furniture Equipment
0.05
+20.51%
0.04
+85.71%
0.02
+50.00%
0.01
Construction In Progress
—
0.01
0.00
—
Other Properties
0.03
+0.00%
0.03
—
—
Leases
0.07
+32.65%
0.05
+133.33%
0.02
+40.00%
0.01
Total Liabilities Net Minority Interest
18.94
-21.86%
24.24
+34.65%
18.00
+448.11%
3.28
Current Liabilities
18.94
-21.48%
24.12
+37.56%
17.53
+433.92%
3.28
Payables And Accrued Expenses
1.82
-59.72%
4.53
+11.66%
4.05
+31.53%
3.08
Payables
0.30
-68.84%
0.97
+17.66%
0.82
-2.96%
0.85
Accounts Payable
0.30
-68.84%
0.97
+17.66%
0.82
-2.96%
0.85
Current Accrued Expenses
1.52
-57.24%
3.56
+10.14%
3.23
+44.57%
2.24
Current Debt And Capital Lease Obligation
0.20
-69.66%
0.66
+90.14%
0.34
+71.64%
0.20
Current Debt
0.08
-10.87%
0.09
+411.11%
0.02
-60.87%
0.05
Current Capital Lease Obligation
0.12
-79.26%
0.56
+72.48%
0.33
+110.97%
0.15
Other Current Liabilities
16.91
-10.67%
18.94
+44.18%
13.13
—
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.12
-74.89%
0.47
0.00
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.12
-74.89%
0.47
0.00
Long Term Capital Lease Obligation
0.00
-100.00%
0.12
-74.89%
0.47
0.00
Stockholders Equity
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Common Stock Equity
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Capital Stock
0.02
+100.00%
0.01
-68.57%
0.04
+133.33%
0.01
Common Stock
0.02
+100.00%
0.01
-68.57%
0.04
+133.33%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
22.11
+94.25%
11.38
+227.55%
3.48
+128.18%
1.52
Ordinary Shares Number
22.11
+94.25%
11.38
+227.55%
3.48
+128.18%
1.52
Additional Paid In Capital
158.00
+45.37%
108.69
+79.07%
60.70
+81.10%
33.52
Retained Earnings
-127.83
-26.22%
-101.27
-56.91%
-64.54
-89.84%
-34.00
Gains Losses Not Affecting Retained Earnings
-0.00
0.00
—
—
Other Equity Adjustments
-0.00
—
—
—
Total Equity Gross Minority Interest
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Total Capitalization
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Working Capital
30.02
+339.70%
6.83
+265.13%
-4.13
-546.09%
-0.64
Invested Capital
30.28
+302.49%
7.52
+298.44%
-3.79
-802.62%
-0.42
Total Debt
0.20
-74.26%
0.77
-4.69%
0.81
+303.48%
0.20
Capital Lease Obligations
0.12
-82.82%
0.68
-14.12%
0.79
+411.61%
0.15
Net Tangible Assets
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Tangible Book Value
30.20
+306.37%
7.43
+295.09%
-3.81
-717.38%
-0.47
Dueto Related Parties Current
—
—
—
—
Line Of Credit
0.08
-10.87%
0.09
+411.11%
0.02
-60.87%
0.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-31.32
-9.60%
-28.57
-56.29%
-18.28
-16.82%
-15.65
Cash Flow From Continuing Operating Activities
-31.32
-9.59%
-28.58
-56.30%
-18.28
-16.82%
-15.65
Net Income From Continuing Operations
-26.55
+27.70%
-36.73
-20.25%
-30.54
-69.14%
-18.06
Depreciation Amortization Depletion
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
Depreciation
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
Depreciation And Amortization
0.57
+33.64%
0.43
+50.70%
0.28
+76.40%
0.16
Other Non Cash Items
—
0.00
—
0.02
Pension And Employee Benefit Expense
—
—
—
0.00
Stock Based Compensation
2.64
+12.38%
2.35
+32.99%
1.77
+68.77%
1.05
Operating Gains Losses
-2.02
-134.83%
5.80
-43.69%
10.30
—
Gain Loss On Investment Securities
-2.02
-134.83%
5.80
-43.69%
10.30
—
Change In Working Capital
-5.95
-1294.38%
-0.43
-359.14%
-0.09
-107.89%
1.18
Change In Prepaid Assets
-2.88
-251.71%
-0.82
+26.59%
-1.12
-1901.61%
0.06
Change In Payables And Accrued Expense
-2.50
-417.09%
0.79
-38.09%
1.28
+0.71%
1.27
Change In Payable
-2.50
-417.09%
0.79
-38.09%
1.28
+0.71%
1.27
Change In Account Payable
-2.50
-417.09%
0.79
-38.09%
1.28
+0.71%
1.27
Change In Other Current Liabilities
-0.56
-42.32%
-0.40
-57.54%
-0.25
-66.89%
-0.15
Investing Cash Flow
-12.10
-16698.61%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Cash Flow From Continuing Investing Activities
-12.10
-16698.61%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Net PPE Purchase And Sale
-0.02
+66.67%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Purchase Of PPE
-0.02
+66.67%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Capital Expenditure
-0.02
+66.67%
-0.07
-500.00%
-0.01
-500.00%
-0.00
Net Investment Purchase And Sale
-12.07
0.00
—
—
Purchase Of Investment
-12.07
0.00
—
—
Financing Cash Flow
46.47
+3.06%
45.09
+63.71%
27.54
+5947.35%
-0.47
Cash Flow From Continuing Financing Activities
46.47
+3.06%
45.09
+63.71%
27.54
+5947.35%
-0.47
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
46.58
+6720.20%
0.68
0.00
-100.00%
0.01
Cash Dividends Paid
0.00
+100.00%
-1.09
0.00
—
Proceeds From Stock Option Exercised
1.50
0.00
—
0.00
Net Other Financing Charges
-1.61
+64.22%
-4.50
-69.88%
-2.65
-449.59%
-0.48
Changes In Cash
3.06
-81.41%
16.44
+77.82%
9.25
+157.34%
-16.12
Beginning Cash Position
26.14
+169.48%
9.70
+2032.09%
0.46
-97.26%
16.58
End Cash Position
29.20
+11.69%
26.14
+169.48%
9.70
+2032.09%
0.46
Free Cash Flow
-31.34
-9.40%
-28.65
-56.58%
-18.30
-16.88%
-15.65
Interest Paid Supplemental Data
0.00
-100.00%
0.01
-50.00%
0.02
+300.00%
0.01
Income Tax Paid Supplemental Data
—
0.00
0.00
0.00
Common Stock Issuance
46.58
+6720.20%
0.68
0.00
-100.00%
0.01
Issuance Of Capital Stock
46.58
-8.09%
50.68
+67.88%
30.19
+274354.55%
0.01
Net Preferred Stock Issuance
0.00
-100.00%
50.00
+65.62%
30.19
0.00
Preferred Stock Issuance
0.00
-100.00%
50.00
+65.62%
30.19
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category